Target
HRRm
3 abstracts
Abstract
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,
Abstract
Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Institut Gustave Roussy, National Cancer Center Hospital East, Kashiwa, Japan, Auckland City Hospital and University of Auckland, Vall d’Hebron University Hospital/VHIO,
Abstract
Frequency of somatic mutations in solid tumor malignancies from inner city minorities: A single center study.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,